<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="780">
  <stage>Registered</stage>
  <submitdate>14/09/2005</submitdate>
  <approvaldate>14/09/2005</approvaldate>
  <nctid>NCT00168519</nctid>
  <trial_identification>
    <studytitle>Contraction (Exercise) Mediated Glucose Uptake as a Therapeutic Target in Type 2 Diabetes</studytitle>
    <scientifictitle>Contraction Mediated Glucose Uptake as a Therapeutic Target in Type 2 Diabetes</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>51/02</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Diabetes Mellitus, Type 2</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - nitroprusside, pentalong, imdur, AICAR, isoptin

Active Comparator: 1 - 


Treatment: drugs: nitroprusside, pentalong, imdur, AICAR, isoptin
Sodium Nitroprusside - one 30 minute intravenous infusion
Pentalong - two tablets orally (total 160mg)
Imdur - two tablets orally (total 120mg)

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>glucose metabolism</outcome>
      <timepoint>3 hours</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients with type 2 diabetes

          -  Non-smokers

          -  Free of overt coronary disease (stress ECG)

          -  Body mass index &lt; 35 kg.m-2

          -  Fasting plasma glucose &gt; 7 mmol.L-1 and / or post 75 gm oral glucose load plasma
             glucose levels of &gt; 11.1 mmol.L-1

          -  Unmedicated (diet controlled)

        Healthy controls

          -  Non-smokers

          -  Free of overt coronary disease (ECG)

          -  Body mass index &lt; 30 kg.m-2

          -  Fasting plasma glucose &lt; 6.1 mmol.L-1

          -  Unmedicated</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Male</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria />
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2002</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/04/2009</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Baker Heart Research Institute - Melbourne</hospital>
    <postcode>8008 - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Baker Heart Research Institute</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>National Health and Medical Research Council, Australia</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Hoffmann-La Roche</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Diabetes Australia</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this project is to determine whether glucose metabolism can be improved by
      administering a substance (nitric oxide donor) normally released by muscles during exercise.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00168519</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Bronwyn A Kingwell, PhD</name>
      <address>Baker Heart Research Institute</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>